Research programme: 5T4 monoclonal antibody conjugates - Oxford BioMedica/Pfizer
Alternative Names: 5T4 MAb-toxin; Anti-5T4 antibody; CME-548; OBA1-H8Latest Information Update: 04 Nov 2017
At a glance
- Originator Oxford BioMedica
- Developer Pfizer
- Class Aminoglycosides; Antineoplastics; Drug conjugates; Enediynes; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Immunomodulators; Membrane glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 06 Sep 2013 Preclinical development in Cancer is ongoing in USA
- 04 May 2011 Oxford BioMedica broadens 5T4 antibody collaboration with Pfizer; Pfizer granted non-exclusive rights for the diagnostic use of 5T4 antibodies in an amendment to an existing licensing agreement